{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+B3&page=2",
    "query": {
      "intervention": "Cohort B3",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+B3&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T21:30:59.697Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02336165",
      "title": "Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Standard radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "Ludwig Institute for Cancer Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 159,
      "start_date": "2015-02-26",
      "completion_date": "2021-07-06",
      "has_results": true,
      "last_update_posted_date": "2022-10-12",
      "last_synced_at": "2026-09-25T21:30:59.697Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • San Francisco, California • Baltimore, Maryland + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02336165"
    },
    {
      "nct_id": "NCT02101736",
      "title": "Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "NF1",
        "Neurofibromatosis",
        "Plexiform Neurofibromas"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2014-06",
      "completion_date": "2022-02-16",
      "has_results": true,
      "last_update_posted_date": "2023-05-24",
      "last_synced_at": "2026-09-25T21:30:59.697Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02101736"
    },
    {
      "nct_id": "NCT05000216",
      "title": "COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis (RA)",
        "Systemic Lupus Erythematosus (SLE)",
        "Pemphigus Vulgaris",
        "Multiple Sclerosis (MS)",
        "Systemic Sclerosis (SSc)",
        "Pediatric SLE",
        "Juvenile Idiopathic Arthritis (JIA)",
        "Juvenile Dermatomyositis (JDM)",
        "Pediatric-Onset Multiple Sclerosis (POMS)"
      ],
      "interventions": [
        {
          "name": "Moderna mRNA-1273",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad26.COV2.S",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Continue IS (MMF or MPA)",
          "type": "DRUG"
        },
        {
          "name": "Continue IS (MTX)",
          "type": "DRUG"
        },
        {
          "name": "Continue IS (B cell depletion therapy)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Monovalent [B.1.351] CoV2 preS dTM-AS03",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Withhold IS (MMF or MPA)",
          "type": "DRUG"
        },
        {
          "name": "Withhold IS (MTX)",
          "type": "DRUG"
        },
        {
          "name": "Withhold IS (B cell depletion therapy)",
          "type": "DRUG"
        },
        {
          "name": "Moderna mRNA-1273, Bivalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2, Bivalent",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 258,
      "start_date": "2021-08-13",
      "completion_date": "2024-03-28",
      "has_results": true,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-09-25T21:30:59.697Z",
      "location_count": 29,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05000216"
    },
    {
      "nct_id": "NCT05827926",
      "title": "A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV-2",
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Influenza Vaccine 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1083.1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1083.2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1083.3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational Influenza Vaccine 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational COVID-19 Vaccine 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "COVID-19 Vaccine 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational Influenza Vaccine 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Influenza Vaccine 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1083",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational COVID-19 Vaccine 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "COVID-19 Vaccine 2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 1758,
      "start_date": "2023-04-14",
      "completion_date": "2024-12-03",
      "has_results": true,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-09-25T21:30:59.697Z",
      "location_count": 69,
      "location_summary": "Chandler, Arizona • Colton, California • Huntington Beach, California + 59 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Modesto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05827926"
    },
    {
      "nct_id": "NCT02264678",
      "title": "Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Administration of ceralasertib",
          "type": "DRUG"
        },
        {
          "name": "Administration of ceralasertib in combination with olaparib",
          "type": "DRUG"
        },
        {
          "name": "Administation of ceralasertib in combination with durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Administration of ceralasertib monotherapy",
          "type": "DRUG"
        },
        {
          "name": "Administration of ceralasertib and olaparib",
          "type": "DRUG"
        },
        {
          "name": "Administration of ceralasertib and durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Administration of ceralasertib in combination with AZD5305",
          "type": "DRUG"
        },
        {
          "name": "Administration of ceralasertib in combination with carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 358,
      "start_date": "2014-10-31",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-09-25T21:30:59.697Z",
      "location_count": 8,
      "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02264678"
    },
    {
      "nct_id": "NCT02795767",
      "title": "A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Emicizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 88,
      "start_date": "2016-07-22",
      "completion_date": "2020-11-11",
      "has_results": true,
      "last_update_posted_date": "2021-06-02",
      "last_synced_at": "2026-09-25T21:30:59.697Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02795767"
    },
    {
      "nct_id": "NCT06704724",
      "title": "A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Pancreatic Ductal",
        "Colorectal Neoplasms",
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "PF-07985045",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cetuximab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Fluorouracil",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Oxaliplatin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Leucovorin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Bevacizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Sasanlimab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "pemetrexed",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cisplatin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Paclitaxel",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Carboplatin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "PF-07284892",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-12-10",
      "completion_date": "2026-05-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-09-25T21:30:59.697Z",
      "location_count": 12,
      "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 6 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06704724"
    },
    {
      "nct_id": "NCT04029922",
      "title": "Study of MT-5111 in HER2-positive Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-positive Solid Cancers"
      ],
      "interventions": [
        {
          "name": "MT-5111 (experimental study drug)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Molecular Templates, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2019-11-12",
      "completion_date": "2023-04-27",
      "has_results": false,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-09-25T21:30:59.697Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Fullerton, California • Los Alamitos, California + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04029922"
    },
    {
      "nct_id": "NCT03492125",
      "title": "A Study Of The Selective PKC-β Inhibitor MS- 553",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma",
        "Aggressive Lymphoma"
      ],
      "interventions": [
        {
          "name": "MS-553",
          "type": "DRUG"
        },
        {
          "name": "acalabrutinib",
          "type": "DRUG"
        },
        {
          "name": "venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "obinutuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MingSight Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2018-05-25",
      "completion_date": "2023-11-28",
      "has_results": true,
      "last_update_posted_date": "2025-04-10",
      "last_synced_at": "2026-09-25T21:30:59.697Z",
      "location_count": 5,
      "location_summary": "Ann Arbor, Michigan • New York, New York • Columbus, Ohio + 2 more",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03492125"
    },
    {
      "nct_id": "NCT04422210",
      "title": "A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2020-09-22",
      "completion_date": "2020-11-06",
      "has_results": true,
      "last_update_posted_date": "2021-11-08",
      "last_synced_at": "2026-09-25T21:30:59.697Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04422210"
    }
  ]
}